Reports Q4 revenue $30M, consensus $28.34M. Joe Todisco, CorMedix (CRMD) CEO, commented, “I am proud of the Company’s recent progress as we execute on our launch objectives and increase patient access to DefenCath across settings of care. We have seen continued growth from existing customers throughout the first quarter and we are focused on growing our patient base in 2025 with both existing and new accounts.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- Cormedix: Buy Rating Affirmed Amid Growth Potential and Strategic LDO Partnerships
- Morning Movers: Mobileye jumps following Volkswagen ADAS partnership
- Cormedix: Positive Outlook with Strategic Advancements and Strong Financial Performance
- Options Volatility and Implied Earnings Moves Today, March 25, 2025
- Options Volatility and Implied Earnings Moves This Week, March 24 – March 27, 2025